{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glycopyrronium%2FFormoterol+Fumarate",
    "query": {
      "intervention": "Glycopyrronium/Formoterol Fumarate"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glycopyrronium%2FFormoterol+Fumarate&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T09:19:36.058Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04609878",
      "title": "Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "BGF MDI 320/28.8/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BGF MDI 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF MDI 320/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF pMDI 320/9 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 2274,
      "start_date": "2020-12-15",
      "completion_date": "2025-03-21",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 107,
      "location_summary": "Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more",
      "locations": [
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04609878"
    },
    {
      "nct_id": "NCT05830071",
      "title": "A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "CHF5993",
          "type": "DRUG"
        },
        {
          "name": "CHF5259",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400mg",
          "type": "DRUG"
        },
        {
          "name": "CHF5993 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 95,
      "start_date": "2023-03-29",
      "completion_date": "2023-10-13",
      "has_results": false,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05830071"
    },
    {
      "nct_id": "NCT02497001",
      "title": "A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "BGF MDI 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "GFF MDI (PT003) 14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF MDI (PT009) 320/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "Symbicort® Turbuhaler® (TBH) Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 1902,
      "start_date": "2015-08-10",
      "completion_date": "2018-01-05",
      "has_results": true,
      "last_update_posted_date": "2020-12-24",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 63,
      "location_summary": "Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02497001"
    },
    {
      "nct_id": "NCT07103642",
      "title": "EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "BGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 3402,
      "start_date": "2024-08-15",
      "completion_date": "2024-10-18",
      "has_results": false,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07103642"
    },
    {
      "nct_id": "NCT06067828",
      "title": "A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: Budesonide and Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Treatment C : Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 171,
      "start_date": "2023-10-24",
      "completion_date": "2026-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Tarzana, California • Torrance, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Anderson",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06067828"
    },
    {
      "nct_id": "NCT06723756",
      "title": "A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Treatment A: BGF MDI HFO",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: BGF MDI HFA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 105,
      "start_date": "2025-01-23",
      "completion_date": "2025-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06723756"
    },
    {
      "nct_id": "NCT01980615",
      "title": "Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Inhaled BGF (PT010) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Inhaled BGF (PT010) Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Inhaled BGF (PT010) Dose 3",
          "type": "DRUG"
        },
        {
          "name": "Inhaled GFF (PT003)",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Symbicort Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Symbicort Dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 84,
      "start_date": "2013-11",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-14",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01980615"
    },
    {
      "nct_id": "NCT02268396",
      "title": "Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 138,
      "start_date": "2014-11",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-12-23",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 10,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02268396"
    },
    {
      "nct_id": "NCT02454959",
      "title": "Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "GFF MDI (PT003) with Aerochamber",
          "type": "DEVICE"
        },
        {
          "name": "GFF MDI (PT003) without Aerochamber",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2015-05-01",
      "completion_date": "2016-03-25",
      "has_results": true,
      "last_update_posted_date": "2017-04-19",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 6,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 3 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454959"
    },
    {
      "nct_id": "NCT02196714",
      "title": "PK Study of PT003 and PT001 in Japanese Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-10-02T09:19:36.058Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02196714"
    }
  ]
}